3 búsqueda de la palabra clave 'neuroendocrine tumors'

A Serous Cystic Tumor and a Pancreatic Neuroendocrine Tumor in the Same Patient: A Case Report and Literature Review / Vanessa García Gómez ; Aguilar Sr, Alexander ; Ortiz, Santiago ; Vélez Garcés, Sara  

Público ISBD Título : A Serous Cystic Tumor and a Pancreatic Neuroendocrine Tumor in the Same Patient: A Case Report and Literature Review Tipo de documento : documento electrónico Autores : Vanessa García Gómez, Autor ; Aguilar Sr, Alexander, Autor ; Ortiz, Santiago, Autor ; Vélez Garcés, Sara, Autor Fecha de publicación : 2024 Títulos uniformes : Cureus Idioma : Inglés (eng) Palabras clave : pancreatic cyst  magnetic resonance imaging  serous neoplasms  pancreatic neoplasms  neuroendocrine tumors Resumen : A serous cystic tumor is a rare entity that has a benign course. Its imaging characteristics, such as the presence of multiple cysts with or without nodular enhancement, can simulate other cystic or solid lesions of the pancreas. Identification of the enhancing scar with punctate calcifications on computed tomography (CT) or magnetic resonance imaging (MRI) may be a distinctive finding suggesting this diagnosis. Neuroendocrine tumors of the pancreas are a different and also rare entity. In images, they have early arterial enhancement. In MRI, they are hyperintense on T2 and hypointense on T1, with avid contrast enhancement. A case of a patient with two focal lesions in the pancreas is presented and the importance of integrating clinical findings, semiology in diagnostic images and, if applicable, the histopathological result for the optimal management of pancreatic tumors is illustrated, highlighting the crucial role of a radiologist in this process. Mención de responsabilidad : Alexander Aguilar Sr. , Vanessa García Gómez , Santiago Ortiz , Sara Vélez Garcés Referencia : Cureus. 2024 May 27;16(5):e61159 DOI (Digital Object Identifier) : 10.7759/cureus.61159 PMID : 38933621 Derechos de uso : CC BY-NC-ND En línea : https://pmc.ncbi.nlm.nih.gov/articles/PMC11202097/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis A Serous Cystic Tumor and a Pancreatic Neuroendocrine Tumor in the Same Patient: A Case Report and Literature Review [documento electrónico] / Vanessa García Gómez, Autor ; Aguilar Sr, Alexander, Autor ; Ortiz, Santiago, Autor ; Vélez Garcés, Sara, Autor . - 2024. Obra : Cureus Idioma : Inglés (eng) Palabras clave : pancreatic cyst  magnetic resonance imaging  serous neoplasms  pancreatic neoplasms  neuroendocrine tumors Resumen : A serous cystic tumor is a rare entity that has a benign course. Its imaging characteristics, such as the presence of multiple cysts with or without nodular enhancement, can simulate other cystic or solid lesions of the pancreas. Identification of the enhancing scar with punctate calcifications on computed tomography (CT) or magnetic resonance imaging (MRI) may be a distinctive finding suggesting this diagnosis. Neuroendocrine tumors of the pancreas are a different and also rare entity. In images, they have early arterial enhancement. In MRI, they are hyperintense on T2 and hypointense on T1, with avid contrast enhancement. A case of a patient with two focal lesions in the pancreas is presented and the importance of integrating clinical findings, semiology in diagnostic images and, if applicable, the histopathological result for the optimal management of pancreatic tumors is illustrated, highlighting the crucial role of a radiologist in this process. Mención de responsabilidad : Alexander Aguilar Sr. , Vanessa García Gómez , Santiago Ortiz , Sara Vélez Garcés Referencia : Cureus. 2024 May 27;16(5):e61159 DOI (Digital Object Identifier) : 10.7759/cureus.61159 PMID : 38933621 Derechos de uso : CC BY-NC-ND En línea : https://pmc.ncbi.nlm.nih.gov/articles/PMC11202097/ Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD002202	AC-2024-055	Archivo digital	Producción Científica	Artículos científicos	Disponible

65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update / Luis Vicente Syro Moreno  

Público ISBD Título : 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Chemotherapy  neoplasms  neuroendocrine tumors  pituitary  temozolomide Resumen : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. DOI (Digital Object Identifier) : 10.1530/ERC-18-0015 PMID : 29535142 En línea : https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis 65 YEARS OF THE DOUBLE HELIX: Treatment of pituitary tumors with temozolomide: an update [documento electrónico] / Luis Vicente Syro Moreno,  . - 2018. Obra : Endocrine Related Cancer Idioma : Inglés (eng) Palabras clave : Chemotherapy  neoplasms  neuroendocrine tumors  pituitary  temozolomide Resumen : Temozolomide is an alkylating chemotherapeutic agent used in malignant neuroendocrine neoplasia, melanoma, brain metastases and an essential component of adjuvant therapy in the treatment of glioblastoma multiforme and anaplastic astrocytoma. Since 2006, it has been used for the treatment of pituitary carcinomas and aggressive pituitary adenomas. Here, we discuss the current indications and results of temozolomide therapy in pituitary tumors, as well as frequently asked questions regarding temozolomide treatment, duration of therapy, dosage, tumor recurrence and resistance. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Leon D Ortiz, Kalman Kovacs Referencia : Endocr Relat Cancer. 2018 Aug;25(8):T159-T169. DOI (Digital Object Identifier) : 10.1530/ERC-18-0015 PMID : 29535142 En línea : https://erc.bioscientifica.com/view/journals/erc/25/8/ERC-18-0015.xml Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000800	AC-2018-087	Archivo digital	Producción Científica	Artículos científicos	Disponible

Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions / Luis Vicente Syro Moreno  

Público ISBD Título : Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions Tipo de documento : documento electrónico Autores : Luis Vicente Syro Moreno, Fecha de publicación : 2018 Títulos uniformes : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Alkylating agents  chemotherapy  DNA repair  neoplasms  neuroendocrine tumors  O(6)-Methylguanine-DNA Methyltransferase  pituitary  temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Temozolomide and pituitary tumors: current understanding, unresolved Issues, and future directions [documento electrónico] / Luis Vicente Syro Moreno,  . - 2018. Obra : Frontiers in Endocrinology Idioma : Inglés (eng) Palabras clave : Alkylating agents  chemotherapy  DNA repair  neoplasms  neuroendocrine tumors  O(6)-Methylguanine-DNA Methyltransferase  pituitary  temozolomide Resumen : Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-year progression-free survival in both aggressive pituitary adenomas and pituitary carcinomas. In this paper, we review the mechanism of action of temozolomide as alkylating agent, its interaction with deoxyribonucleic acid repair systems, therapeutic effects in pituitary tumors, unresolved issues, and future directions relating to new possibilities of targeted therapy. Mención de responsabilidad : Luis V Syro, Fabio Rotondo, Mauricio Camargo, Leon D Ortiz, Carlos A Serna, Kalman Kovacs Referencia : Front Endocrinol (Lausanne). 2018 Jun 15;9:318 DOI (Digital Object Identifier) : 10.3389/fendo.2018.00318 PMID : 29963012 En línea : https://www.frontiersin.org/articles/10.3389/fendo.2018.00318/full Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Reserva

Reservar este documento

Ejemplares(1)

Código de barras	Número de Ubicación	Tipo de medio	Ubicación	Sección	Estado
DD000777	AC-2018-064	Archivo digital	Producción Científica	Artículos científicos	Disponible